FindTrial
Sign In

EFFECT OF ORMELOXIFENE IN WOMEN WITH ABNORMAL UTERINE BLEEDING AN INTERVENTIONAL STUDY

A STUDY ON ORMELOXIFENE IN MANAGEMENT OF ABNORMAL UTERINE BLEEDING

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037387
Enrollment
52
Registered
2021-10-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: 1- Obstetrics Health Condition 2: 1- Obstetrics

Interventions

Intervention1: ORMELOXIFENE: SELECTIVE ESTROGEN RECEPTOR MODULATOR Tab.ORMELOXIFENE 60MG ORALLY TWICE A WEEK FOR 12 WEEKS FOLLOWED BY ONCE A WEEK FOR ANOTHER 12 WEEKS . Intervention2: Ormeloxifene:

Sponsors

SHRI BM PATIL MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.BLEEDING MORE THAN 8 DAYS WITH HEAVY MENSTRUAL BLEEDING 2.PATIENT DIAGNOSED WITH AUB

Exclusion criteria

Exclusion criteria: 1.PELVIC PATHOLOGIES LIKE SUSPECTED ADENOMYOSIS , UTERINE FIBROIDS , MALIGNANCIES OF UTERUS / CERVIX/ OVARY/VAGINA/ENDOMETRIAL HYPERPLASIA WITH ATYPIA 2.MEDICAL DISEASES LIKE - LIVER DYSFUNCTION , HEART DISEASE , MIGRAINE, STROKE , RENAL DISEASES , PLATELET DISORDERS OR COAGULOPATHY , PREVIOUS HISTORY OF THROMBOSIS , PREGNANCY , ABORTION , USE OF IUCD OR ORAL CONTRACEPTIVES , LACTATION WOMEN IN FURST 6 MONTHS OF POST NATAL PERIOD , HYPERSENSITIVITY OT THE DRUG

Design outcomes

Primary

MeasureTime frame
by measuring the menstrual blood lossTimepoint: at 12 weeks and 24 weeks—

Secondary

MeasureTime frame
acceptability and side effects of ormeloxifeneTimepoint: 3rd and 6th month—

Countries

India

Contacts

Public ContactDr Karumuri Priyanka

SHRI BM PATIL MEDICAL COLLEGE HOSPITAL AND RESEARCH

shailaja.bidri@bldedu.ac.in9605415233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026